Ucb Pharma Gmbh

Schwarz Pharma Ag

Lts Lohmann Therapie-systeme Ag

Ucb Biopharma Sprl

Ucbbiopharma Srl

Christoph Arth

Hans-Michael Wolff

Michael Komenda

Fatima Bicane

Walter Müller

Luc Quere

Hans-Jürgen Mika

Stephan Rimpler

Andreas Kollmeyer-Seeger

Claus Meese

Walter Mueller

Hans Lindner

Kerstin Paulus

Dietrich Wilhelm Schacht

Hans-Jurgen Mika

Meike Irngartinger

The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.

Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine

The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.

Pharmaceutical compositions comprising Fesoterodine

Pharmaceutical compositions comprising fesoterodine

The invention relates to a transdermal therapeutic system (TTS) for transcutaneously administering tolterodine over a period of several days and to a method for producing the same. The TTS contains a self-adhesive layer-shaped matrix composition which contains a (meth)acrylate copolymer comprising ammonium groups. The TTS also contains at least one plasticizer and up to 25 wt, % of tolterodine.

Transdermal therapeutic system TTS containing tolterodine

A transdermal therapeutic system for transcutaneous administration of sexual steroid hormones over long time periods, and a solvent-free method for the production thereof, is disclosed. The steroid hormones are subjected to as little thermal exposure as possible, thereby avoiding decomposition of the steroid hormones.

Transdermal therapeutic system (TTS) for administering sexual steroid hormones

A stable therapeutical transdermal system for the transcutaneous delivery of levonorgestrel, alone or together with other sex steroid hormones, over a long time period is disclosed. A method of producing the transdermal system that avoids the use of solvents and avoids degradation of the steroid hormones also is disclosed.

Therapeutical system for transdermal delivery of levonorgestrel

A transdermal therapeutic system (TTS) for transcutaneous administration of oxybutynin over a period of several days, in addition to a method for the production of the TTS without the use of solvents, are disclosed. The TTS contains a matrix mass containing oxybutynin in the form of a self-adhesive layer. The matrix mass includes ammonium-group-containing (meth)acrylic polymers, at least one citric acid ester, and 5-25 wt. % oxybutynin.

Transdermal therapeutic system (TTS) containing oxybutynin

The invention relates to a transdermal therapeutic system (TTS) for the transcutaneous administration of pergolide over several days and to a method for its manufacture without using solvents. The TTS contains a matrix mass, containing pergolide and taking the form of a layer, which contains a (meth)acrylate copolymer containing ammonio groups or a mixture of a (meth)acrylate copolymer containing amino groups and a (meth)acrylate polymer containing carboxyl groups, 10-50% by weight propylene glycol and up to 5% by weight pergolide.

Transdermal therapeutic system containing pergolide

Growing community of inventors

Düsseldorf, Germany

Christoph Arth